E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets.

E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets.
Curr Cancer Drug Targets. 2016 Feb 16;
Authors: Huang Y, Chen R, Zhou J
Abstract
Inflammation is the fundamental protective immuno-response and frequently occurred in organisms including humen beings. However, disordered response can cause chronic human disease, including cancer. Inflammatory cells and mediators are essential to the tumor microenvironment, and dissection of this complex molecular and cellular milieu may elucidate a connection between cancer and inflammation. Thus, focusing on transcription factor NF-κB and E2F1 in inflammation-associated cancer is urgent. NF-κB activation is prevalent in carcinomas, mainly driven by inflammatory cytokines in the tumor microenvironment. E2F1 is also involved in regulating immune responses. Understanding the crosstalk between the two pathways and the behind regulating mechanisms may contribute to the development of novel anti-cancer therapeutics.
PMID: 26881929 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - February 16, 2016 Category: Cancer & Oncology Authors: Huang Y, Chen R, Zhou J Tags: Curr Cancer Drug Targets Source Type: research